Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma's product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound.

Ensifentrine met the primary endpoint in both ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in lung function. In addition, ensifentrine significantly reduced the rate of COPD exacerbations in ENHANCE-1 and ENHANCE-2. 

We are led by a management team with an established track record in the discovery, development and commercialization of respiratory therapies. 

Verona Pharma is listed on the Nasdaq Global Market in the United States under the ticker symbol VRNA. We are headquartered in London, UK, and have offices in Raleigh and Savannah in the US.

For more information, please visit https://www.veronapharma.com.


Silicon Valley Bank

Oxford Finance LLC

Hercules Capital

Soleus Capital

Perceptive Advisors

Abingworth

Samsara BioCapital

Foresite Capital

New Enterprise Associates

David Ebsworth

Mark W. Hahn

Martin Edwards

Verona Pharma

Our Pharmacovigilance team is expanding! We are excited to welcome George Phillips, Pharm.D. as Verona’s new Vice President, Pharmacovigilance. With over 40 years of #pharma experience, George will lead oversight of investigational and postmarketing drug safety as we prepare for the potential approval and launch of #ensifentrine.

It was an exciting night for #VeronaPharma as we attended the #2023ScripAwards, where we were recognized with nominations in three categories.
We are delighted to announce CEO David Zaccardelli won Executive of the Year.
Read more here: http://bit.ly/3MLXhZj

As the third leading cause of death globally, #COPD is a progressive #lung disease that affects approximately 392 million people worldwide. Today, on #WorldCOPDDay2023, we recognize that COPD is underdiagnosed and undertreated, with millions of patients remaining symptomatic on available therapies. 
 
Verona Pharma is committed to developing drugs for chronic respiratory diseases including COPD.
 
Learn more about the importance of early diagnosis and early interventions for COPD: https://bit.ly/3Mq8xdR

We’re proud to partner with the Global Initiative for Chronic Obstructive Lung Disease as a Platinum Sponsor for the annual GOLD International COPD Conference in Philadelphia, PA. 
 
#GOLDCOPD2023 helps educate healthcare providers about the latest #COPD research and evidence-based strategies for COPD management from leading experts around the globe.
 
We support GOLD in its efforts to raise awareness of #COPD and improve prevention and treatment of this lung disease around the globe.

It is a busy month for Verona Pharma as we participate in multiple investor conferences. We look forward to engaging with industry experts and investors as we prepare for the potential US approval of our investigational #COPD treatment, #ensifentrine, with a PDUFA date of June, 26, 2024. 
 
Jefferies Piper Sandler Evercore  

Today, our management team will share the financial results for the third quarter, ended September 30, 2023, and provide a corporate update for the investment community. This includes an overview of our commercial planning for our investigational drug, ensifentrine, which is under review by the US Food and Drug Administration with a target action date of June 26, 2024.

Listen to the webcast here: https://bit.ly/49muLHw
#COPD #VRNA

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue					1.84M -	2.78K 99.85%	2.35K 15.52%		40M -	458K 98.86%
cost of revenue							512.11K -	627.85K 22.60%		346K -	679.62K 96.42%
gross profit					1.84M -	2.78K 99.85%	-509.76K 18,416.92%	-627.85K 23.17%	40M 6,470.99%	112K 99.72%	-679.62K 706.81%
selling and marketing expenses									22.24M -	19.38M 12.87%
general and administrative expenses	1.91M -	1.80M 5.80%	2.51M 39.42%	2.89M 15.19%	8.10M 179.71%	7.99M 1.37%	8.99M 12.64%	29.77M 231.00%	11.66M 60.83%	7.20M 38.28%
selling general and administrative expenses	1.91M -	1.80M 5.80%	2.51M 39.42%	2.89M 15.19%	8.10M 179.71%	7.99M 1.37%	8.99M 12.64%	29.77M 231.00%	33.91M 13.89%	26.58M 21.61%	49.87M 87.62%
research and development expenses	2.73M -	4.10M 50.14%	10.76M 162.45%	5.58M 48.17%	32.05M 474.49%	24.48M 23.62%	43.89M 79.28%	44.51M 1.40%	79.41M 78.42%	49.28M 37.94%	17.28M 64.93%
other expenses			1.17M -	1.07M 8.88%	23K 97.85%	16.50K 28.28%	527.09K 3,095.44%	-8.27M 1,668.43%	-15.63M 89.06%	-9.63M 38.36%
cost and expenses	4.64M -	5.90M 27.09%	13.29M 125.14%	8.49M 36.15%	40.16M 373.26%	32.48M 19.12%	53.41M 64.43%	66.01M 23.58%	97.68M 47.98%	66.57M 31.85%	67.83M 1.89%
operating expenses	4.64M -	5.90M 27.09%	13.29M 125.14%	8.49M 36.15%	40.16M 373.26%	32.48M 19.12%	53.41M 64.43%	66.01M 23.58%	97.68M 47.98%	66.23M 32.20%	67.15M 1.39%
interest expense				104.52K -	98.65K 5.61%		221.59K -	35K 84.20%	340K 871.43%	521K 53.24%	2.06M 296.35%
ebitda	-4.58M -	-5.82M 27.01%	-13.21M 126.97%	-9.18M 30.53%	-39.50M 330.35%	-31.27M 20.84%	-51.76M 65.56%	-65.27M 26.08%	-57.04M 12.60%	-62.66M 9.85%	-67.15M 7.17%
operating income	-4.64M -	-5.90M 27.09%	-13.29M 125.14%	-8.66M 34.83%	-40.21M 364.26%	-32.47M 19.25%	-53.87M 65.88%	-74.28M 37.89%	-73.31M 1.30%	-66.12M 9.82%	-67.83M 2.59%
depreciation and amortization	61.99K -	82.43K 32.98%	78.69K 4.54%	76.03K 3.38%	166.22K 118.63%	124.35K 25.19%	2.10M 1,590.20%	9.01M 328.73%	16.27M 80.59%	3.46M 78.76%	679.62K 80.34%
total other income expenses net	4.34K -	46.66K 975.07%	66.36K 42.22%	1.29M 1,847.81%	6.15M 376.04%	1.85M 69.93%	2.46M 33.03%	9.28M 276.95%	17.73M 91.07%	-2.33M 113.16%	12.62M 641.11%
income before tax	-4.64M -	-5.86M 26.21%	-13.22M 125.80%	-7.37M 44.28%	-34.06M 362.20%	-30.62M 10.09%	-51.41M 67.87%	-65M 26.45%	-55.59M 14.48%	-68.45M 23.14%	-55.21M 19.34%
income tax expense	-477.22K -	-1.56M 227.48%	-2.24M 43.09%	-1.18M 47.35%	-6.36M 440.21%	-5.37M 15.56%	-9.53M 77.39%	146K 101.53%	-18K 112.33%	253K 1,505.56%	-632.44K 349.98%
net income	-4.16M -	-4.29M 3.14%	-10.99M 155.90%	-6.19M 43.65%	-27.70M 347.37%	-25.25M 8.83%	-41.88M 65.84%	-65.15M 55.55%	-55.57M 14.70%	-68.70M 23.63%	-54.58M 20.55%
weighted average shs out	426.96M -	1.08B 153.76%	1.26B 16.52%	2.09B 65.85%	109.69M 94.76%	131.39M 19.79%	13.17M 89.98%	32.87M 149.64%	59.15M 79.97%	66.13M 11.81%	79.27M 19.86%
weighted average shs out dil	426.96M -	1.08B 153.76%	1.26B 16.52%	2.09B 65.85%	109.69M 94.76%	131.39M 19.79%	13.17M 89.98%	32.87M 149.64%	59.15M 79.97%	66.13M 11.81%	79.27M 19.86%
eps	-0.10 -	-0.04 59.38%	-0.09 119.70%	-0.03 65.98%	-2.53 8,447.30%	-0.19 92.49%	-3.18 1,573.68%	-1.98 37.74%	-0.94 52.53%	-1.04 10.64%	-0.69 33.65%
epsdiluted	-0.10 -	-0.04 59.38%	-0.09 119.70%	-0.03 65.98%	-2.53 8,447.30%	-0.19 92.49%	-3.18 1,573.68%	-1.98 37.74%	-0.94 52.53%	-1.04 10.64%	-0.69 33.65%

NASDAQ:VRNA

Verona Pharma plc

Last Close

26.01

30/08 20:00

Market Cap

1.45B

Beta: 0.18

Volume Today

1.22M

Avg: 566.41K

PE Ratio

−222.62

PFCF: −30.88

Preview